Biohaven Ltd. (BHVN): Insider Trading, Congress Trades & Research | Tormere

BHVN

$15.23-2.43%visit website

Biohaven Ltd.

Market Cap

$2.3B

Live price × SEC shares (Oct 26, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

3.11

49mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Sep 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Research & development	121,945	103,827	100,814	101,850	428,436
Operating income	(142,734)	(130,428)	(124,899)	(126,420)	(524,481)
Pretax income	(145,204)	(130,260)	(136,920)	(129,343)	(541,727)
Income tax	351	272	391	(64)	950
Net income	(145,555)	(130,532)	(137,311)	(129,279)	(542,677)
EPS (basic) ($)		(0.88)	(0.91)	(0.86)	—
EPS (diluted) ($)		(0.88)	(0.91)	(0.86)	—
Weighted avg. shares (basic)		147,615	150,637	151,040
Weighted avg. shares (diluted)		147,615	150,637	151,040

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Oct 29, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 17 more quarters, back to Sep 2021, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Pfizer Inc. Q3 2026 Earnings Call Summary

Yahoo · 2026-11-03

Biohaven Ltd. Stock 12‑Month Price Target Raised to $25, Implies 65% Upside

TradingView · 2026-11-03

symbol__ Stock Quote Price and Forecast

CNN · 2026-11-02

Biohaven Consensus Price Target Increased 10.16% to $24.48

Fintel · 2026-11-02

Biohaven Ltd. (BHVN) stock price, news, quote and history

Yahoo Finance Australia · 2026-11-01

Biohaven Stock Losses Narrow As Kidney Drug Data Shows Early Promise

Simply Wall St · 2026-10-31

Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32

Benzinga · 2026-10-30

Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?

Yahoo · 2026-10-30

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

Yahoo · 2026-10-29

A drug deal could bring Biohaven $400 million, with $350 million at closing

Stock Titan · 2026-10-29

Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate

Benzinga · 2026-10-29

Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade

Yahoo · 2026-10-29

JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

Yahoo · 2026-10-26

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

Yahoo · 2026-10-26

Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026

Benzinga · 2026-10-26

Informational purposes only, not investment advice.